Response to Cottu, Bozec, Basse, and Paoletti.

While awaiting further evidence from large multinational cohort studies, as discussed in our analysis, it might be beneficial to continue curative surgical resections, chemotherapy, and other cancer treatments based on an individual patient evaluation. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The overall case fatality rate of COVID19 patients with cancer measured 22.4%, which is comparable with that of the authors' report from a single institute (2) and recent meta-analysis involving similar populations from other multinational cohorts (3,4). [Extracted from the article]